Immunotherapies: Southern Research has helped biopharma innovators turn bold immunotherapy ideas into clinic-ready realities for more than eighty years. We provide a seamless suite of immunogenicity and translational immunology services that spans ADA and neutralizing-antibody analyses, cytokine-release and T-cell functional assays, and rapid, multi-species efficacy models that mirror today’s checkpoint-inhibitor, mRNA/LNP and cell-therapy pipelines. Our evaluation strategy bundles assay design, bioanalysis and regulatory-grade reporting, trimming decision-making timelines while giving sponsors budget clarity. At the Immunotherapies Exchange, we look forward to exploring how our collaborative scientists can become an extension of your team, translating mechanistic insight into clear go/no-go choices that accelerate immune-modulating candidates toward first-in-human studies.

ADC: Southern Research is redefining bioanalytical support for the next generation of antibody–drug conjugates by combining deep mechanistic insight with the operational rigor of our GLP-compliant BSL-1/2/3 facilities. Our scientists deploy high-resolution mass spectrometry and orthogonal LC methods to elucidate linker stability and drug-to-antibody ratios, then couple those data with 3-D tumor-spheroid platforms that quantify intracellular trafficking and bystander effects under physiologically relevant conditions. Integrated PK, safety, and tox programs seamlessly link in vitro findings with in vivo models, generating the cohesive data packages regulators now expect for IND submissions. During the ADC Therapeutics Exchange round-table, we will share how this assay innovation shortens CMC and clinical timelines, de-risks development, and partners with sponsors to unlock the full therapeutic promise of ADC 2.0.